3D-Printed Drugs for Children-Are We Ready Yet?

Maren Preis, Heidi Öblom

Research output: Contribution to journalArticleScientificpeer-review

46 Citations (Scopus)

Abstract

The first medicine manufactured by three-dimensional (3D) printing was recently approved by the Food and Drug Administration (FDA). The advantages of printing as a manufacturing route enabling more flexibility regarding the dose, and enlarging individual treatment options, have been demonstrated. There is a particular need for flexible drug delivery solutions when it comes to children. Printing as a new pharmaceutical manufacturing technology brings manufacturing closer to the patient and can easily be adjusted to the required dosing scheme, offering more flexibility for treatments. Printing of medicine may therefore become the manufacturing route of choice to provide tailored and potentially on-demand treatments for patients with individual needs. This paper intends to summarize and discuss the state of the art, the crucial aspects which should be taken into account, and the still-open questions, in order to make 3D printing a suitable manufacturing route for pediatric drugs.
Original languageUndefined/Unknown
Pages (from-to)303–308
Number of pages6
JournalAAPS PharmSciTech
Volume18
Issue number2
DOIs
Publication statusPublished - 2017
MoE publication typeA1 Journal article-refereed

Keywords

  • pediatrics
  • 3D printing

Cite this